USRE38919E1 - Injectable microfoam containing a sclerosing agent - Google Patents
Injectable microfoam containing a sclerosing agent Download PDFInfo
- Publication number
- USRE38919E1 USRE38919E1 US10/458,806 US45880603A USRE38919E US RE38919 E1 USRE38919 E1 US RE38919E1 US 45880603 A US45880603 A US 45880603A US RE38919 E USRE38919 E US RE38919E
- Authority
- US
- United States
- Prior art keywords
- microfoam
- injectable
- substance
- sclerosing
- injecting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A61K9/122—Foams; Dry foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/07—Microporous membranes
Definitions
- SchlerosisSclerosis of varices is based on injecting liquid substances in them, which causing a localized inflammatory reaction propitiates the elimination of these abnormal veins.
- a mixture thereof with the blood contained in the vein is produced and diluted in an unknown proportion.
- the results are uncertain (due to overdose or underdose) and limited to short varicose segments.
- the size of the varices to be injected decreases, the lesser this dilution is and the results that are obtained are more foreseeable.
- sclerosis is a technique chosen in cases of small and medium-sized varices. Surgery is used for those varices with a diameter equal to larger than 7 mm.
- Orbach In 1946 Orbach injected in small caliber varices some few cubic centimeters of air and verified displacement of the blood inside the vessel, which is occupied by the injected air.
- the sclerosing agent introduced afterwards is more effective than if it has been injected into the blood.
- This invention refers to the preparation of a sclerosing microfoam.
- the lifting of the injected member decreases even more the venous pressure, facilitating the exclusive filling of the vein with microfoam; this remaining in the vessel while the patient is not lifted from the examination table.
- microfoam prepared with a sclerosing agent Upon replacing the prepared microfoam with the physiological serum by microfoam prepared with a sclerosing agent and injecting it in the vein, this displaces the blood that the vein contains and guarantees the contact of the sclerosis agent with the endothelium of the vein, at a known concentration and for a controllable amount of time, achieving sclerosis of the entire occupied segment.
- the elaboration of the present invention is carried out with the preparation of a microfoam with any sclerosing agent, such as: polydocanol polidocanol, sodium tetradecly tetradecyl sulfate, hypertonic glucosated or glucosaline solutions, chromated glycerol, ethanolamine oleate, sodium morrhuate, iodated solutions.
- any sclerosing agent such as: polydocanol polidocanol, sodium tetradecly tetradecyl sulfate, hypertonic glucosated or glucosaline solutions, chromated glycerol, ethanolamine oleate, sodium morrhuate, iodated solutions.
- the sclerosing microfoam has been prepared by any one of the existing processes, two of which will be described hereinafter, it is introduced in any sterile vessel that can be used later to be injected in the vessels to be treated, and that permits the stability of the same, so that it can be removed by a syringe, or by any other instrument that allows injection thereof into the vessels to be treated.
- the preparation of the sclerosing microfoam is done by mixing in a sterile, hermetic container and connected if desired to a bottle under oxygen pressure, mixture of oxygen and carbon dioxide or other physiological gasses gases; mechanical beating is carried out by means of a micromotor that makes an écouvillon submerged in the sclerosing solution to be foamed turn.
- the microfoam is achieved.
- the sclerosing agent does not have a foaming capacity Polysorbate 20, Polysorbate 80, Polygeline or any other substance with a foaming capacity accepted as inert for intravenous use is added to it.
- the sclerosing agent is introduced into a hermetic, pressurized and sterile container and by stirring the solution the microfoam is achieved, with a outlet from the container for its subsequent use.
- the invention can also embrace prepared or extemporaneously prepared injectable microfoam for therapeutic uses characterized in that the microfoam is prepared with any sclerosing substance.
- the sclerosing substanc in the injectable microfoam is polidocanol.
- it is sodium tetradecyl sulfate.
- it is a hypertonic glucostated or glucosaline solution.
- the sclerosing substance can be chromated glycerol.
- the sclerosing substance in another embodiment is ethanolamine oleate.
- Another embodiment could envisage sodium morrhuate as the sclerosing substance.
- the present invention also uses the inventive microfoam in phlebology.
- the sclerosing substance in the microfoam can be polidocanol or sodium tetradecyl sulfate.
- the present invention also uses the inventive microfoam in the treatment of esophageal varices.
- the sclerosing substance in the microfoam can be polidocanol or sodium tetradecyl sulfate.
- the present invention also uses the inventive microfoam in a proctology.
- the sclerosing substance in the microfoam can be polidocanol or sodium tetradecyl sulfate.
- the present invention also uses the inventive microfoam in angiology.
- the sclerosing substance in the microfoam can be polidocanol or sodium tetradecyl sulfate.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Vascular Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Injectable microfoam for sclerotcraphy. The sclerotherapy of varices is based on the injection of liquid substances capable of suppressing them. The present invention relates to the preparation of sclerosing substances in the form of a microfoam. The microfoam is prepared with sclerosing agents, and is then injected in the vein to be treated, so that the microfoam displaces the blood contained in the vein and provides for the contact of the sclerosing agent with the vascular endothelium, with a predetermined known concentration and during a controllable time.
Description
This is a continuation of international application Serial No. PCT/ES94/00064, filed Jun. 21, 1994.
SchlerosisSclerosis of varices is based on injecting liquid substances in them, which causing a localized inflammatory reaction propitiates the elimination of these abnormal veins.
Upon injecting a sclerosing agent, a mixture thereof with the blood contained in the vein is produced and diluted in an unknown proportion. The results are uncertain (due to overdose or underdose) and limited to short varicose segments. As the size of the varices to be injected decreases, the lesser this dilution is and the results that are obtained are more foreseeable. Nowadays, sclerosis is a technique chosen in cases of small and medium-sized varices. Surgery is used for those varices with a diameter equal to larger than 7 mm.
Sclerosis and surgery complement each other at this time, but sclerotherapy continues without being able to be applied to large varicose trunci.
In these large sized varices, upon injecting a sclerosing substance, the concentration thereof in the vein, its homogenous distribution in the blood and the time that it is going to be in contact with the inside walls of the treted treated vein are unknown.
In 1946 Orbach injected in small caliber varices some few cubic centimeters of air and verified displacement of the blood inside the vessel, which is occupied by the injected air. The sclerosing agent introduced afterwards is more effective than if it has been injected into the blood.
In thick varices, upon injecting air, the described phenomenon of displacement of the blood by the injected air does not take place, but rather this forms a bubble inside the vein that makes the process ineffective in these vessels.
This same author conceived, a few years late later, injection of foam obtained by agitating in a container containing sodium tetradecyl sulfate, an anionic sclerosing detergent with a high foaming capacity.
The process turns out to be rather useless due to the large-sized bubbles formed and dangerous due to the collateral effects of the atmospheric nitrogen, not very soluble in blood.
Both methods had very little practical repercussion as they were used only in small varices.
This invention refers to the preparation of a sclerosing microfoam.
In accordance with the present invention it has been discovered that injecting in a horizontal position a microfoam of pharmacologically inert sterile physiological serum, it is verified that the microfoam causes displacement of the blood contained in the vessel, even in more developed varices, due to the fact that the pressure of the blood contained in them horizontally is low.
The lifting of the injected member decreases even more the venous pressure, facilitating the exclusive filling of the vein with microfoam; this remaining in the vessel while the patient is not lifted from the examination table.
Upon replacing the prepared microfoam with the physiological serum by microfoam prepared with a sclerosing agent and injecting it in the vein, this displaces the blood that the vein contains and guarantees the contact of the sclerosis agent with the endothelium of the vein, at a known concentration and for a controllable amount of time, achieving sclerosis of the entire occupied segment.
The advantages of this process allow:
1. To know the concentration of the sclerosing agent in the vessel, as the microfoam displaces the blood and is not diluted in it like a liquid in it.
2. To guarantee the homogenous distribution of the product of sclerosis in the inside thereof.
3. To control the time in which it is kept in contact with the inside walls of the vein.
All of these factors are not known exactly nor are they controllable with the use of liquid sclerosing agents.
The elaboration of the present invention is carried out with the preparation of a microfoam with any sclerosing agent, such as: polydocanol polidocanol, sodium tetradecly tetradecyl sulfate, hypertonic glucosated or glucosaline solutions, chromated glycerol, ethanolamine oleate, sodium morrhuate, iodated solutions.
Once the sclerosing microfoam has been prepared by any one of the existing processes, two of which will be described hereinafter, it is introduced in any sterile vessel that can be used later to be injected in the vessels to be treated, and that permits the stability of the same, so that it can be removed by a syringe, or by any other instrument that allows injection thereof into the vessels to be treated.
The preparation of the sclerosing microfoam is done by mixing in a sterile, hermetic container and connected if desired to a bottle under oxygen pressure, mixture of oxygen and carbon dioxide or other physiological gasses gases; mechanical beating is carried out by means of a micromotor that makes an écouvillon submerged in the sclerosing solution to be foamed turn.
Beating between 8,000 and 15,000 rpm, for a time between 60 and 120 seconds, the microfoam is achieved.
This is introduced into any container that can be used for subsequent storage and later injection into the veins to be sclerosed.
In the event that the sclerosing agent does not have a foaming capacity Polysorbate 20, Polysorbate 80, Polygeline or any other substance with a foaming capacity accepted as inert for intravenous use is added to it.
The sclerosing agent is introduced into a hermetic, pressurized and sterile container and by stirring the solution the microfoam is achieved, with a outlet from the container for its subsequent use.
The invention can also embrace prepared or extemporaneously prepared injectable microfoam for therapeutic uses characterized in that the microfoam is prepared with any sclerosing substance. In one embodiment, the sclerosing substanc in the injectable microfoam is polidocanol. In another embodiment, it is sodium tetradecyl sulfate. In a further embodiment, it is a hypertonic glucostated or glucosaline solution. In still another embodiment, the sclerosing substance can be chromated glycerol. The sclerosing substance in another embodiment is ethanolamine oleate. Another embodiment could envisage sodium morrhuate as the sclerosing substance. Still another, envisages any iodated solution.
The present invention also uses the inventive microfoam in phlebology. The sclerosing substance in the microfoam can be polidocanol or sodium tetradecyl sulfate.
The present invention also uses the inventive microfoam in the treatment of esophageal varices. The sclerosing substance in the microfoam can be polidocanol or sodium tetradecyl sulfate.
The present invention also uses the inventive microfoam in a proctology. The sclerosing substance in the microfoam can be polidocanol or sodium tetradecyl sulfate.
The present invention also uses the inventive microfoam in angiology. The sclerosing substance in the microfoam can be polidocanol or sodium tetradecyl sulfate.
Claims (36)
1. Prepared or extemporaneously prepared injectable microfoam for therapeutic uses characterized in that the microfoam is prepared with any sclerosing substance.
2. Injectable microfoam for therapeutic uses, according to claim 1 , characterized in that the sclerosing substance is polydocanol.
3. Injectable microfoam for therapeutic uses, according to claim 1 , characterized in that the sclerosing substance is sodium tetradecyl sulfate.
4. Injectable microfoam for therapeutic uses, according to claim 1 , characterized in that the sclerosing substance is a hypertonic glucostated by glucosaline solution.
5. Injectable microfoam for therapeutic uses, according to claim 1 , characterized in that the sclerosing substance used is chromated glycerol.
6. Injectable microfoam for therapeutic uses, according to claim 1 , characterized in that the sclerosing substance used is ethanolamine oleate.
7. Injectable microfoam for therapeutic uses, according to claim 1 , characterized in that the sclerosing substance used is sodium morrhuate.
8. Injectable microfoam for therapeutic uses, according to claim 1 , characterized in that the sclerosing substance used is any iodated solution.
9. A method for phlebologic treatment comprising injecting the microfoam of claim 1 into vessels to be treated.
10. A method for phlebologic treatment comprising injecting the microfoam of claim 2 into vessels to be treated.
11. A method for phlebologic treatment comprising injecting the microfoam of claim 3 into vessels to be treated.
12. A method for treatment of esophageal varices comprising injecting the microfoam of claim 1 into vessels to be treated.
13. A method for treatment of esophageal varices comprising injecting the microfoam of claim 2 into vessels to be treated.
14. A method for treatment of esophageal varices comprising injecting the microfoam of claim 3 into vessels to be treated.
15. A method for proctologic treatment comprising injecting the microfoam of claim 1 into vessels to be treated.
16. A method for proctologic treatment comprising injecting the microfoam of claim 2 into vessels to be treated.
17. A method for proctologic treatment comprising injecting the microfoam of claim 3 into vessels to be treated.
18. A method for angiologic treatment comprising injecting the microfoam of claim 1 into vessels to be treated.
19. A method for angiologic treatment comprising injecting the microfoam of claim 2 into vessels to be treated.
20. A method for angiologic treatment comprising injecting the microfoam of claim 3 into vessels to be treated.
21. An injectable microfoam for therapeutic use that is prepared or extemporaneously prepared comprising
at least one sclerosing substance chosen from polidocanol, sodium tetradecyl sulfate, hypertonic glucosated solutions, hypertonic glucosaline solutions, chromated glycerol, ethanolamine oleate, sodium morrhuate, and iodated solutions, and
wherein the injectable microfoam is made in a container under pressure of oxygen.
22. The injectable microfoam of claim 21 , wherein the at least one sclerosing substance is polidocanol.
23. The injectable microfoam of claim 21 , wherein the microfoam further comprises at least one substance with a foaming capacity.
24. The injectable microfoam of claim 23 , wherein the at least one substance with a foaming capacity is chosen from polysorbate 20, polysorbate 80, and polygeline.
25. An injectable microfoam for therapeutic use that is prepared or extemporaneously prepared comprising
at least one sclerosing substance chosen from polidocanol, sodium tetradecyl sulfate, hypertonic glucosated solutions, hypertonic glucosaline solutions, chromated glycerol, ethanolamine oleate, sodium morrhuate, and iodated solutions, and
wherein the injectable microfoam is made in a container under pressure of a mixture of oxygen and carbon dioxide.
26. The injectable microfoam of claim 25 , wherein the at least one sclerosing substance is polidocanol.
27. The injectable microfoam of claim 25 , wherein the microfoam further comprises at least one substance with a foaming capacity.
28. The injectable microfoam of claim 27 , wherein the at least one substance with a foaming capacity is chosen from polysorbate 20, polysorbate 80, and polygeline.
29. An injectable microfoam for therapeutic use that is prepared or extemporaneously prepared comprising
at least one sclerosing substance chosen from polidocanol, sodium tetradecyl sulfate, hypertonic glucosated solutions, hypertonic glucosaline solutions, chromated glycerol, ethanolamine oleate, sodium morrhuate, and iodated solutions, and
wherein the injectable microfoam is made under pressure of oxygen in a hermetic container.
30. The injectable microfoam of claim 29 , wherein the at least one sclerosing substance is polidocanol.
31. The injectable microfoam of claim 29 , wherein the microfoam further comprises at least one substance with a foaming capacity.
32. The injectable microfoam of claim 31 , wherein the at least one substance with a foaming capacity is chosen from polysorbate 20, polysorbate 80, and polygeline.
33. An injectable microfoam for therapeutic use that is prepared or extemporaneously prepared comprising
at least one sclerosing substance chosen from polidocanol, sodium tetradecyl sulfate, hypertonic glucosated solutions, hypertonic glucosaline solutions, chromated glycerol, ethanolamine oleate, sodium morrhuate, and iodated solutions, and
wherein the injectable microfoam is made under pressure of a mixture of oxygen and carbon dioxide in a hermetic container.
34. The injectable microfoam of claim 33 , wherein the at least one sclerosing substance is polidocanol.
35. The injectable microfoam of claim 33 , wherein the microfoam further comprises at least one substance with a foaming capacity.
36. The injectable microfoam of claim 35 , wherein the at least one substance with a foaming capacity is chosen from polysorbate 20, polysorbate 80, and polygeline.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/458,806 USRE38919E1 (en) | 1993-06-23 | 2003-06-11 | Injectable microfoam containing a sclerosing agent |
US10/941,013 USRE40640E1 (en) | 1993-06-23 | 2004-09-15 | Injectable microfoam containing a sclerosing agent |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES09301413A ES2068151B1 (en) | 1993-06-23 | 1993-06-23 | INJECTABLE MICROS FOAM FOR SCLEROSIS. |
PCT/ES1994/000064 WO1995000120A1 (en) | 1993-06-23 | 1994-06-21 | Injectable microfoam containing a sclerosing agent |
US08/407,595 US5676962A (en) | 1993-06-23 | 1995-02-23 | Injectable microfoam containing a sclerosing agent |
US10/458,806 USRE38919E1 (en) | 1993-06-23 | 2003-06-11 | Injectable microfoam containing a sclerosing agent |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/ES1994/000064 Continuation WO1995000120A1 (en) | 1993-06-23 | 1994-06-21 | Injectable microfoam containing a sclerosing agent |
US08/407,595 Reissue US5676962A (en) | 1993-06-23 | 1995-02-23 | Injectable microfoam containing a sclerosing agent |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/407,595 Continuation US5676962A (en) | 1993-06-23 | 1995-02-23 | Injectable microfoam containing a sclerosing agent |
Publications (1)
Publication Number | Publication Date |
---|---|
USRE38919E1 true USRE38919E1 (en) | 2005-12-13 |
Family
ID=8282315
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/407,595 Ceased US5676962A (en) | 1993-06-23 | 1995-02-23 | Injectable microfoam containing a sclerosing agent |
US10/458,806 Expired - Lifetime USRE38919E1 (en) | 1993-06-23 | 2003-06-11 | Injectable microfoam containing a sclerosing agent |
US10/941,013 Expired - Lifetime USRE40640E1 (en) | 1993-06-23 | 2004-09-15 | Injectable microfoam containing a sclerosing agent |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/407,595 Ceased US5676962A (en) | 1993-06-23 | 1995-02-23 | Injectable microfoam containing a sclerosing agent |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/941,013 Expired - Lifetime USRE40640E1 (en) | 1993-06-23 | 2004-09-15 | Injectable microfoam containing a sclerosing agent |
Country Status (9)
Country | Link |
---|---|
US (3) | US5676962A (en) |
EP (1) | EP0656203B3 (en) |
AT (1) | ATE179598T1 (en) |
AU (1) | AU7001294A (en) |
DE (1) | DE69418286T2 (en) |
DK (1) | DK0656203T3 (en) |
ES (2) | ES2068151B1 (en) |
GR (1) | GR3030248T3 (en) |
WO (1) | WO1995000120A1 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040156915A1 (en) * | 2000-11-24 | 2004-08-12 | Harman Anthony David | Generation of therapeutic microfoam |
US20060049269A1 (en) * | 1999-05-26 | 2006-03-09 | Tariq Osman | Generation of therapeutic microfoam |
US20060062736A1 (en) * | 2003-11-17 | 2006-03-23 | Wright David D I | Therapeutic foam |
US20070003489A1 (en) * | 2003-11-17 | 2007-01-04 | Wright David D I | Therapeutic foam |
US20080031827A1 (en) * | 2001-08-08 | 2008-02-07 | Maria Garcia-Olmedo Dominguez | Injectables in foam. New Pharmaceutical applications |
US20090124704A1 (en) * | 2005-05-13 | 2009-05-14 | William John Jenkins | Therapeutic foam |
US9351945B1 (en) | 2015-02-27 | 2016-05-31 | John Daniel Dobak, III | Reduction of adipose tissue |
US9687455B2 (en) | 2014-08-14 | 2017-06-27 | John Daniel Dobak | Sodium tetradecyl sulfate formulations for treatment of adipose tissue |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2068151B1 (en) | 1993-06-23 | 1995-11-16 | Cabrera Garrido Juan | INJECTABLE MICROS FOAM FOR SCLEROSIS. |
US20060165606A1 (en) | 1997-09-29 | 2006-07-27 | Nektar Therapeutics | Pulmonary delivery particles comprising water insoluble or crystalline active agents |
AU2005205772B2 (en) * | 1999-05-26 | 2009-04-30 | Btg International Limited | Generation of Therapeutic Microfoam |
US8404217B2 (en) | 2000-05-10 | 2013-03-26 | Novartis Ag | Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use |
CA2382133C (en) | 2000-05-10 | 2010-11-23 | Alliance Pharmaceutical Corporation | Phospholipid-based powders for drug delivery |
US7871598B1 (en) | 2000-05-10 | 2011-01-18 | Novartis Ag | Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use |
US7077836B2 (en) * | 2000-07-21 | 2006-07-18 | Vein Rx, Inc. | Methods and apparatus for sclerosing the wall of a varicose vein |
US20030120256A1 (en) * | 2001-07-03 | 2003-06-26 | Syntheon, Llc | Methods and apparatus for sclerosing the wall of a varicose vein |
GB2369996B (en) * | 2000-12-18 | 2004-06-23 | S T D Pharmaceutical Products | Method and apparatus for producing an injectable foam |
WO2003013475A1 (en) * | 2001-08-08 | 2003-02-20 | Garcia-Olmedo Dominguez Maria | Injectable foam and novel pharmaceutical applications thereof |
WO2003053411A1 (en) | 2001-12-19 | 2003-07-03 | Nektar Therapeutics | Pulmonary delivery of aminoglycosides |
WO2003084173A1 (en) * | 2002-03-28 | 2003-10-09 | British Telecommunications Public Limited Company | Synchronisation in multi-modal interfaces |
GB0212047D0 (en) | 2002-05-24 | 2002-07-03 | Btg Int Ltd | Generation of therapeutic microfoam |
GB0300586D0 (en) * | 2003-01-10 | 2003-02-12 | Btg Int Ltd | Therapeutic microfoam |
ES2216708B1 (en) * | 2003-04-08 | 2006-02-16 | Antonio Luis Cabrera Garrido | "AWESOME SOLUTION". |
US7314466B2 (en) * | 2003-10-02 | 2008-01-01 | Lary G Banning | Minimally invasive vascular surgery |
ES2247898B1 (en) * | 2003-12-18 | 2006-12-01 | Universidad Complutense De Madrid | USE OF A PRIOR POLYCHOCAMOL INJECTION IN THE FORM OF MICROSPUMA FOR THE PAINLESS REMOVAL OF VARICES THROUGH LASER. |
ITMI20041056A1 (en) * | 2004-05-26 | 2004-08-26 | Garrido Antonio Luis Cabrera | USE IN THE DIAGNOSTIC MEDICAL FIELD AND LOGICAL FLEBUS OF A KISCELA OF STERILE AND PHYSIOLOGICALLY ACCEPTABLE GASES |
WO2006076699A1 (en) * | 2005-01-14 | 2006-07-20 | Vein Rx, Inc. | Valve system for a medical device having an inflatable member |
EP2010249A2 (en) * | 2006-04-04 | 2009-01-07 | Vnus Medical Technologies, Inc. | Method and apparatus for generating vascular treatment foam |
EP2043531B1 (en) | 2006-06-15 | 2013-01-02 | Cook Medical Technologies LLC | Systems and devices for the delivery of endoluminal prostheses |
US20080050436A1 (en) * | 2006-08-25 | 2008-02-28 | Chu Jack F | Methods and compounds for obliteration of vessels |
US20190070397A1 (en) * | 2006-11-27 | 2019-03-07 | Frank Levy | Apparatus and method for producing co2 enriched medical foam |
CA2672834C (en) | 2006-12-21 | 2015-04-21 | Btg International Limited | Device and method for producing therapeutic foam |
EP2187983B1 (en) | 2007-09-12 | 2014-04-16 | Cook Incorporated | Enhanced remodelable materials for occluding bodily vessels |
US8157747B2 (en) | 2008-02-15 | 2012-04-17 | Lary Research & Development, Llc | Single-use indicator for a surgical instrument and a surgical instrument incorporating same |
US10143455B2 (en) | 2011-07-20 | 2018-12-04 | Covidien LLP | Enhanced ultrasound visualization of intravascular devices |
CA2753207C (en) | 2009-02-20 | 2017-07-11 | Sapheon, Inc. | Methods and devices for venous occlusion for the treatment of venous insufficiency |
WO2012170538A2 (en) | 2011-06-06 | 2012-12-13 | Cook Medical Technologies Llc | Vascular occlusion devices and methods |
US8808620B1 (en) | 2012-02-22 | 2014-08-19 | Sapheon, Inc. | Sterilization process design for a medical adhesive |
JP2012246306A (en) * | 2012-08-22 | 2012-12-13 | Btg Internatl Ltd | Injectable foam preparation, and new pharmaceutical application |
WO2015105878A1 (en) | 2014-01-07 | 2015-07-16 | Covidien Lp | Cyanoacrylate compositions including non-agglomerating radiopaque nanoparticles |
WO2015185554A2 (en) | 2014-06-03 | 2015-12-10 | Enrique Roche Rebollo | Methods, devices, systems and kits for preparing compositions for care and repair of varicose veins |
EP2962681A1 (en) | 2014-07-03 | 2016-01-06 | Swiss VX Venentherapie und Forschung GmbH | Devices and methods for injectable vascular sclerofoams using a carrier made of human blood and uses thereof |
US20160045416A1 (en) * | 2014-08-14 | 2016-02-18 | John Daniel Dobak | Ethanolamine oleate formulations for treatment of adipose tissue |
GB201611778D0 (en) | 2016-07-06 | 2016-08-17 | Provensis Ltd | Method and device for producing foam |
GB201612925D0 (en) * | 2016-07-26 | 2016-09-07 | Provensis Ltd | Method and device for generating injectable foam |
WO2019178579A1 (en) | 2018-03-16 | 2019-09-19 | Boston Scientific Scimed, Inc. | Devices for vein closure |
IT201800006109A1 (en) | 2018-06-07 | 2019-12-07 | POLIDOCANOL FOR USE AS AN IMMUNOMODULATOR | |
US20240149020A1 (en) | 2022-11-04 | 2024-05-09 | Controlled Delivery Systems, Inc. | Catheters for the aspiration controlled delivery of closure agents |
Citations (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR1547768A (en) | 1967-10-09 | 1968-11-29 | Fillable container with pressure relief device | |
US3698453A (en) | 1970-09-01 | 1972-10-17 | Oreal | Device for storing two liquids separately and dispensing them simultaneously under pressure |
US3970219A (en) | 1975-03-03 | 1976-07-20 | Spitzer Joseph G | Aerosol containers for foaming and delivering aerosols and process |
US4019657A (en) | 1975-03-03 | 1977-04-26 | Spitzer Joseph G | Aerosol containers for foaming and delivering aerosols |
US4040420A (en) | 1976-04-22 | 1977-08-09 | General Dynamics | Packaging and dispensing kit |
US4127131A (en) | 1977-06-20 | 1978-11-28 | Johnson & Johnson | Hub assembly for use in the filtration of fluids and method of making the same |
US4276885A (en) | 1979-05-04 | 1981-07-07 | Rasor Associates, Inc | Ultrasonic image enhancement |
US4292972A (en) | 1980-07-09 | 1981-10-06 | E. R. Squibb & Sons, Inc. | Lyophilized hydrocolloio foam |
EP0054728A1 (en) | 1980-12-23 | 1982-06-30 | Intermedicat Gmbh | Catheter assembly |
DE3048744A1 (en) | 1980-12-23 | 1982-07-22 | Metzeler Kautschuk GmbH, 8000 München | Multiple window pane sealed to timber frame - with elastomer strip and sealing cpd. laid in groove of elastomer |
EP0077752A2 (en) | 1981-10-16 | 1983-04-27 | Schering Aktiengesellschaft | Liquid mixture for absorbing and stabilizing gas bubbles to be used as contrast agent in ultrasonic diagnosis and process for its preparation |
EP0123235A2 (en) | 1983-04-15 | 1984-10-31 | Schering Aktiengesellschaft | Microparticles and ultrasonic contrast means containing gas bubbles |
EP0131540A2 (en) | 1983-07-06 | 1985-01-16 | Schering Aktiengesellschaft | Contrast agent for ultrasounds and its preparation |
DE3050812C2 (en) | 1980-12-23 | 1985-03-21 | B. Braun Melsungen Ag, 3508 Melsungen | Catheterization device |
EP0217582A2 (en) | 1985-09-16 | 1987-04-08 | Unilever Plc | Package for mixing and dispensing |
DE8704600U1 (en) | 1987-03-27 | 1987-10-15 | Cocon Kunststoffen B.V., Arkel | Device for the ready-to-use preparation of the two components of a two-component assembly foam, in particular polyurethane foam |
US4718433A (en) | 1983-01-27 | 1988-01-12 | Feinstein Steven B | Contrast agents for ultrasonic imaging |
DE3417182C2 (en) | 1984-05-09 | 1989-01-19 | Gerald Dr. 8000 Muenchen De Hauer | |
EP0324938A1 (en) | 1987-12-29 | 1989-07-26 | Molecular Biosystems, Inc. | Concentrated stabilized microbubble-type ultrasonic imaging agent and method of production |
EP0359246A2 (en) | 1988-09-14 | 1990-03-21 | Molecular Biosystems, Inc. | Continuous sonication method for preparing protein encapsulated microbubbles |
US5064103A (en) | 1990-05-23 | 1991-11-12 | Rjs Industries, Inc. | Foam dispenser having a plurality of sieves |
US5084011A (en) | 1990-01-25 | 1992-01-28 | Grady Daniel J | Method for oxygen therapy using hyperbarically oxygenated liquid |
WO1992005806A1 (en) * | 1990-10-05 | 1992-04-16 | Sintetica S.A. | Method for the preparation of stable suspensions of hollow gas-filled microspheres suitable for ultrasonic echography |
FR2672038A1 (en) | 1991-01-25 | 1992-07-31 | Oreal | Device for dispensing foam from a pressurised container |
US5141738A (en) | 1983-04-15 | 1992-08-25 | Schering Aktiengesellschaft | Ultrasonic contrast medium comprising gas bubbles and solid lipophilic surfactant-containing microparticles and use thereof |
WO1995000120A1 (en) | 1993-06-23 | 1995-01-05 | Juan Cabrera Garrido | Injectable microfoam containing a sclerosing agent |
US5542935A (en) | 1989-12-22 | 1996-08-06 | Imarx Pharmaceutical Corp. | Therapeutic delivery systems related applications |
WO1996025194A1 (en) | 1995-02-17 | 1996-08-22 | Durand Limited | Medication and apparatus and method of applying medication |
US5623085A (en) | 1994-09-23 | 1997-04-22 | Rohm And Haas Company | Method for reducing microfoam in a spray-applied waterborne composition |
US5656200A (en) | 1993-01-23 | 1997-08-12 | Henkel Kommanditgesellschaft Auf Aktien | Foaming emulsions |
US5902225A (en) | 1994-10-11 | 1999-05-11 | Monson; James A. | Post foamable multiple-sequential-foaming composition |
WO1999043371A1 (en) | 1998-02-27 | 1999-09-02 | Alain Monfreux | Device for producing foam in a syringe body |
FR2775436A1 (en) | 1998-02-27 | 1999-09-03 | Alain Monfreux | Syringe for parenteral administration of substance in foam form |
EP0997396A1 (en) | 1998-10-28 | 2000-05-03 | Kurt Vogelsang GmbH | Cap for two-components aerosol container |
WO2000024649A1 (en) | 1997-05-07 | 2000-05-04 | Giltech Limited | Packaging system for mixing and dispensing multicomponent products |
WO2000066274A1 (en) | 1999-05-03 | 2000-11-09 | Francisco Javier Garcia Mingo | Device for producing foamed sclerosing agent |
WO2000072821A1 (en) | 1999-05-26 | 2000-12-07 | Btg International Limited | Generation of therapeutic microfoam |
US6561237B1 (en) | 2000-11-28 | 2003-05-13 | Brasscorp Ltd. | Apparatus and method for urging fluid into a pressurized system |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3955720A (en) | 1972-11-15 | 1976-05-11 | Malone David C | Low pressure dispensing apparatus with air pump |
CH676456A5 (en) | 1988-04-05 | 1991-01-31 | Supermatic Kunststoff Ag | |
NL9300517A (en) | 1993-03-23 | 1994-10-17 | Airspray Int Bv | Foam forming assembly, a suitable spray head and a spray can comprising such an assembly. |
-
1993
- 1993-06-23 ES ES09301413A patent/ES2068151B1/en not_active Expired - Lifetime
-
1994
- 1994-06-21 DE DE69418286T patent/DE69418286T2/en not_active Ceased
- 1994-06-21 EP EP94918886A patent/EP0656203B3/en not_active Expired - Lifetime
- 1994-06-21 ES ES94918886T patent/ES2131689T7/en active Active
- 1994-06-21 AU AU70012/94A patent/AU7001294A/en not_active Abandoned
- 1994-06-21 WO PCT/ES1994/000064 patent/WO1995000120A1/en active IP Right Grant
- 1994-06-21 AT AT94918886T patent/ATE179598T1/en active
- 1994-06-21 DK DK94918886T patent/DK0656203T3/en active
-
1995
- 1995-02-23 US US08/407,595 patent/US5676962A/en not_active Ceased
-
1999
- 1999-05-19 GR GR990401341T patent/GR3030248T3/en unknown
-
2003
- 2003-06-11 US US10/458,806 patent/USRE38919E1/en not_active Expired - Lifetime
-
2004
- 2004-09-15 US US10/941,013 patent/USRE40640E1/en not_active Expired - Lifetime
Patent Citations (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR1547768A (en) | 1967-10-09 | 1968-11-29 | Fillable container with pressure relief device | |
US3698453A (en) | 1970-09-01 | 1972-10-17 | Oreal | Device for storing two liquids separately and dispensing them simultaneously under pressure |
US3970219A (en) | 1975-03-03 | 1976-07-20 | Spitzer Joseph G | Aerosol containers for foaming and delivering aerosols and process |
US4019657A (en) | 1975-03-03 | 1977-04-26 | Spitzer Joseph G | Aerosol containers for foaming and delivering aerosols |
US4040420A (en) | 1976-04-22 | 1977-08-09 | General Dynamics | Packaging and dispensing kit |
US4127131A (en) | 1977-06-20 | 1978-11-28 | Johnson & Johnson | Hub assembly for use in the filtration of fluids and method of making the same |
US4276885A (en) | 1979-05-04 | 1981-07-07 | Rasor Associates, Inc | Ultrasonic image enhancement |
US4292972A (en) | 1980-07-09 | 1981-10-06 | E. R. Squibb & Sons, Inc. | Lyophilized hydrocolloio foam |
EP0054728A1 (en) | 1980-12-23 | 1982-06-30 | Intermedicat Gmbh | Catheter assembly |
DE3048744A1 (en) | 1980-12-23 | 1982-07-22 | Metzeler Kautschuk GmbH, 8000 München | Multiple window pane sealed to timber frame - with elastomer strip and sealing cpd. laid in groove of elastomer |
DE3050812C2 (en) | 1980-12-23 | 1985-03-21 | B. Braun Melsungen Ag, 3508 Melsungen | Catheterization device |
EP0077752A2 (en) | 1981-10-16 | 1983-04-27 | Schering Aktiengesellschaft | Liquid mixture for absorbing and stabilizing gas bubbles to be used as contrast agent in ultrasonic diagnosis and process for its preparation |
US4466442A (en) * | 1981-10-16 | 1984-08-21 | Schering Aktiengesellschaft | Carrier liquid solutions for the production of gas microbubbles, preparation thereof, and use thereof as contrast medium for ultrasonic diagnostics |
US4718433A (en) | 1983-01-27 | 1988-01-12 | Feinstein Steven B | Contrast agents for ultrasonic imaging |
EP0123235A2 (en) | 1983-04-15 | 1984-10-31 | Schering Aktiengesellschaft | Microparticles and ultrasonic contrast means containing gas bubbles |
CA1232837A (en) | 1983-04-15 | 1988-02-16 | Jurgen Hilmann | Ultrasound contrast agent containing microparticles and gas micro-bubbles |
US5141738A (en) | 1983-04-15 | 1992-08-25 | Schering Aktiengesellschaft | Ultrasonic contrast medium comprising gas bubbles and solid lipophilic surfactant-containing microparticles and use thereof |
EP0131540A2 (en) | 1983-07-06 | 1985-01-16 | Schering Aktiengesellschaft | Contrast agent for ultrasounds and its preparation |
DE3417182C2 (en) | 1984-05-09 | 1989-01-19 | Gerald Dr. 8000 Muenchen De Hauer | |
EP0217582A2 (en) | 1985-09-16 | 1987-04-08 | Unilever Plc | Package for mixing and dispensing |
DE8704600U1 (en) | 1987-03-27 | 1987-10-15 | Cocon Kunststoffen B.V., Arkel | Device for the ready-to-use preparation of the two components of a two-component assembly foam, in particular polyurethane foam |
EP0324938A1 (en) | 1987-12-29 | 1989-07-26 | Molecular Biosystems, Inc. | Concentrated stabilized microbubble-type ultrasonic imaging agent and method of production |
EP0359246A2 (en) | 1988-09-14 | 1990-03-21 | Molecular Biosystems, Inc. | Continuous sonication method for preparing protein encapsulated microbubbles |
US5542935A (en) | 1989-12-22 | 1996-08-06 | Imarx Pharmaceutical Corp. | Therapeutic delivery systems related applications |
US5084011A (en) | 1990-01-25 | 1992-01-28 | Grady Daniel J | Method for oxygen therapy using hyperbarically oxygenated liquid |
US5064103A (en) | 1990-05-23 | 1991-11-12 | Rjs Industries, Inc. | Foam dispenser having a plurality of sieves |
WO1992005806A1 (en) * | 1990-10-05 | 1992-04-16 | Sintetica S.A. | Method for the preparation of stable suspensions of hollow gas-filled microspheres suitable for ultrasonic echography |
FR2672038A1 (en) | 1991-01-25 | 1992-07-31 | Oreal | Device for dispensing foam from a pressurised container |
US5656200A (en) | 1993-01-23 | 1997-08-12 | Henkel Kommanditgesellschaft Auf Aktien | Foaming emulsions |
US5676962A (en) | 1993-06-23 | 1997-10-14 | Cabrera Garrido; Juan | Injectable microfoam containing a sclerosing agent |
DE69418286T2 (en) | 1993-06-23 | 1999-10-14 | Btg International Ltd. | Injectable microfoam that contains a sclerosing agent |
ES2068151A1 (en) | 1993-06-23 | 1995-04-01 | Cabrera Garrido Juan | Injectable microfoam containing a sclerosing agent. |
WO1995000120A1 (en) | 1993-06-23 | 1995-01-05 | Juan Cabrera Garrido | Injectable microfoam containing a sclerosing agent |
EP0656203A1 (en) | 1993-06-23 | 1995-06-07 | Juan Cabrera Garrido | Injectable microfoam containing a sclerosing agent |
US5623085A (en) | 1994-09-23 | 1997-04-22 | Rohm And Haas Company | Method for reducing microfoam in a spray-applied waterborne composition |
US5902225A (en) | 1994-10-11 | 1999-05-11 | Monson; James A. | Post foamable multiple-sequential-foaming composition |
WO1996025194A1 (en) | 1995-02-17 | 1996-08-22 | Durand Limited | Medication and apparatus and method of applying medication |
WO2000024649A1 (en) | 1997-05-07 | 2000-05-04 | Giltech Limited | Packaging system for mixing and dispensing multicomponent products |
WO1999043371A1 (en) | 1998-02-27 | 1999-09-02 | Alain Monfreux | Device for producing foam in a syringe body |
FR2775436A1 (en) | 1998-02-27 | 1999-09-03 | Alain Monfreux | Syringe for parenteral administration of substance in foam form |
EP0997396A1 (en) | 1998-10-28 | 2000-05-03 | Kurt Vogelsang GmbH | Cap for two-components aerosol container |
WO2000066274A1 (en) | 1999-05-03 | 2000-11-09 | Francisco Javier Garcia Mingo | Device for producing foamed sclerosing agent |
WO2000072821A1 (en) | 1999-05-26 | 2000-12-07 | Btg International Limited | Generation of therapeutic microfoam |
US6561237B1 (en) | 2000-11-28 | 2003-05-13 | Brasscorp Ltd. | Apparatus and method for urging fluid into a pressurized system |
Non-Patent Citations (99)
Title |
---|
A. Lemaire et al., "Effect of Intra-arterial oxygen injection on blood cholesterol", Therapie, vol. 13, pp. 395-399, 1958, with Abstract in English. |
A. Ochsner et al., "Comparative Value of Intravenous Sclerosing Substances", Archives of Surgery, vol. 29, No. 3, pp. 397-416, Sep. 1934. |
A. Schmler, "Clinical Comparison of Sclerosing Solutions in Injection Treatment of Varicose Veins, Delayed Slough: Recurrence of Varices", The American Journal of Surgey, vol. XXXVI, No. 1, pp. 389-398, Apr. 1937. |
B. Ya Varshavskii, "Mechanism of Changes in Renal Activity Following intravenous oxygen", vol. 53, No. 2, pp. 173-177, 1967, with Abstract in English. |
De L'Academie des Sciences, Conformement A Une Decision de L'Academie, pp. 890-892, Jan. 1930 and translation into English. |
DVD #1 and #2 containing video clips shown during interview of Jan. 7, 2004. |
E. J. Orbach, "Contributions to the Therapy of the Varicose Complex", Journal of the International College of Surgeons, pp. 765-771, Jun. 1950. |
E. J. Orbach, "The Place of Injection Therapy in the Treatment of Venous Disorders of the Lower Extremity-with Comments on its Technique", Presented at the Annual Meeting of the International College of Angiology, London, pp. 18-23, Jul. 1965. |
E. Orbach, "Leg Ulcers of Vascular Origin and Their Therapy" The American Journal of Surgery, vol. LXXXI, No. 5, pp. 568-572, May 1951. |
E.J. Orbach et al.; "The Thrombogenic Property of Foam of a Synthetic Anionic Detergent (Sodium Tetradecyl Sulfate N.N.R.)", Angiol 1, pp. 237-243; 1950. |
E.J. Orbach, "Schlerotherapy of Varicose Veins", American Journal of Surgery, vol. LXVI, No. 3, pp. 362-366, Dec. 1944. |
E.J. Orbach; "Sclerotherapy of Varicose Veins-Utilization of an Intravenous Air Block"; American Journal of Surgery; vol. LXVI, No. 3, pp. 362-366; Dec. 1944. |
F.B. Cockett, "Arterial Complications during Surgery and Sclerotherapy of Varicose Veins", Phlebology, vol. 1, pp. 3-6, 1986. |
F.W. Runnicliffe et al., "The Intravenous Injection of Oxygen Gas as a Therapeutic Measure", Lancet, vol. II, pp. 321-323, 1916, with Abstract in English. |
G. de Takats et al., "Division of the Popliteal Vein In Deep Venous Insufficiency of the Lower Extremities", Society for Vascular Surgery Issue, vol. 29., No. 3, pp. 342-354, Mar. 1951. |
G. de Takats et al., "The Injection Treatment of Varicose Veins", Surgery, Gynecology and Obstetrics, vol. L, No. 3, pp. 545-561, Mar. 1930. |
G. de Takats, "Ambulatory Ligation of the Saphenous Vein", The Journal of the American Medical Association, vol. 94, No. 16, pp. 1194-1197, Apr. 19, 1930. |
G. Galata, "Intravenous Injection of Oxygen in Dogs", Archivio di Fisiologia, vol. 21, pp. 331-350, 1923, with Abstract in English. |
G. Mayer, "The Treatment of Varicose Veins from the point of View of Sclerotherapy, in particularly on the Basis of Varicophtine", Münchener Medizinische Wochenschrift, vol. 16, No. 20, Columns 1037-1039, Jan. 1952 and translation into English. |
G. Miserey et al., "Sclerose Sous Echographie Dans Certaines Zones a Risques", Phlebologie, vol. 44, No. 1, pp. 85-96, 1991. |
German Nullity Action Complaint filed Jul. 27, 2001 and translation into English. |
German Nullity Action Decision by German Court in English dated Feb. 4, 2003. |
German Nullity Action English Translation of the Substantiation of Appeal to the Federal Court of Justice on Sep. 26, 2003. |
German Nullity Action First Brief filed Dec. 3, 2001 and translation into English. |
German Nullity Action Kreusler Brief filed Jan. 27, 2003 and translation into English. |
German Nullity Action Supplemental Brief filed Dec. 31, 2002 and translation into English. |
German Nullity Action; English Translation of the Reply to appeal dated Feb. 12, 2004. |
H. Biegeleisen, "Fatty Acid Solutions for the Injection Treatment of Varicose Veins", Annals of Surgery, vol. CV, pp. 610-615, 1937. |
H. Harkins et al., "Embolism by Air and Oxygen: Comparative Studies", Proceedings of the Society for Experimental Biology and Medicine, vol. 32, pp. 178-181, 1934-35. |
H. Jausion, "Glycerine Chromee et Sclerose des Ectasies Veineuses", La Presse Medicale, No. 53, pp. 1061-1063, Jul. 5, 1933. |
H. Leonhardt, "On the Treatment of Extensive Formation of Varicose Veins with Ligature of the v. Saphena and Varicoid Injection Through Ditally Inserted Ureteral Catheter", Ärztliche Wochenschrift, vol. 7, No. 3, pp. 56-58, Jan. 1952 and translation into English. |
H. Rogge, "On the dangers of sclerosing recurring varicose veins", Deutsche Medizinische Wochenschrift, No. 9, p. 301, 1950 and translation into English. |
H. Wefers et al., "Results of Injection Treatment with Regard to Extreme Varication", Zentralblatt für Chirurgie, Issue No. 43, pp. 1825-1828, 1952 and translation into English. |
H.E. Lockhart-Mummery et al., "Varicose Ulcer-A Study of the Deep Veins with Special Reference to Retrograde Venography", The British Journal of Surgery, vol. XXXVIII, No. 151, pp. 284-295, Jan. 1951. |
H.G. Oden, "Can the Results of the Treatment of Varicose Vains and Ulcus Cruris be Improved?", Münchener, Medizinische Wochenschrift, vol. 22, No. 8, pp. 364, Jan. 1952 and translation into English. |
I. Singh, "Life Without Breathing", Arch. int. Pharmacodyn., vol. CXXXVII, No. 3-4, pp. 318-330, 1962. |
I.S. Tunick et al., "Sodium Morrhuate as a Sclerosing Agent in the Treatment of Varicose Veins", Annals of Surgery, vol. XCV, pp. 734-737, 1932. |
Jan-Christoph G.R. Wollmann, MD, "The History of Sclerosing Foams", Dermatol Surg. vol. 30, No. 5, pp. 694-703, May 2004. |
K. Biegeleisen et al., "Inadvertent Intra-Arterial Injection Complicating Ordinary and Ultrasound-Guided Sclerotherapy", Phlebology, vol. 19, pp. 953-958, 1993. |
K. Sigg, "Newer Aspects of the Technique of Treating Varicosities", Therapeutishce Umschau, vol. 6, pp. 127-134, 1949 and translation into English. |
K. Sigg, "The Foamed Rubber Compression for Phlebitis and for Phlebitic and Varicose Complications", Die Medizinische, No. 27-28, pp. 910-915, Jul. 1952 and translation into English. |
K. Sigg, "The Treatment of Varicosities and Accompanying Complications", Angiology, The Journal of Vascular Diseases, vol. 3, No. 5, pp. 355-379, Oct. 1952. |
K10-E. Rabe et al.; "Guidelines to Sclerosing Treatment of Varicose Veins"; Leitlinien der DGP, Phlebologie; vol. 6, pp. 154-158; 2001 and translation into English. |
K11-DE 3417182 C2 and EP 0 054 728 and translations into English. |
K12-K. Sigg, "Newer Aspects of the Technique of Treating Varicosities", Therpeutishce Umschau, vol. 6, pp. 127-134, 1949 and translation into English. |
K13-M. Schadeck; "Duplex Controlled Sclerosing Treatment of the Great Saphenous Vein"; Phlebol; vol. 25, pp. 78-82; 1996 and translation into English. |
K14-R. Rowden-Foote; "Varicose Veins Hemorrhoids and Other Conditions-Their Treatment by Injection"; London, H.K. Lewis & Co. Ltd.; pp. 13-45, 106-119; 1944. |
K15-A. Ree; "The Treatment of Varicose Veins with Etamolin Foam"; Acta Dermato-Venereologica; vol. 39, pp. 428-432; 1959. |
K16-E.J. Orbach et al.; "The Thromobogenic Property of Foam of a Synthetic Anionic Detergent (Sodium Tetradecyl Sulfate N.N.R.)", Angiol 1, pp. 237-243; 1950. |
K17-M.D.H.-D. Bock; "Varicosis and its Therapy"; Ärztliche Praxis; XIX vol., No. 60, pp. 2146-2148; Jul. 29, 1967 and translation into English. |
K18-O. Henschel;"Die Varizenverördening-Verördungstherapie mit Aethoxysklerol-Kreussler"; p. 22; 1968 and translation into English. |
K19-13 Pr. Dr. rer. nat. Reinhard Höhler ; "The Expression <<Micro Foam>> is Neither Generally Known to Experts in the Field nor Well-defined"; Laboratoire de Physique de Milieux Diviséet Interfaces Université de Marne-la-Vallée and translation into English. |
K1-Von P. Flückiger, "Nicht-operative retrograde Varicenverödung mit Varsylschaum", Schweizerische Medizinische Wochenschrift, No. 48, pp. 1368-1370, (1956) with English translation. |
K20-Chronologia der Schaumverödung. |
K21-J. Orbach, "Sclerotherapy of varicose Veins", American Journal of Surgery, vol. LXVI, No. 3, pp. 362-366, Dec. 1944. |
K22-J.R. Cabrera Garrido et al., "Extending the Limits of Sclerotherapy: New Sclerosing Products", Phlébp;pgoe, vol. 50, No. 2, pp. 181-188, 1997. |
K23-J. Cabrera; "Application Techniques for Sclerosant in Micro-Foam Form"; pp. 39-44. |
K24-Video (VHS) tape of Compression Sclerotherapy, H.R., Bernbach, M.D. and English Translation of the Documentation Accompanying the Video K24; pp. 1-16. |
K25-Dr. J.C. Wollmann et al.; Evaluation of the Test; Kreussler Pharma; pp. 17-28, Jan. 29, 2003. |
K26-Pr. Dr. R. Höhler ; "The Indication of the Rotation Speed and the Duration of the Rotation is not Sufficient for Foams Produced by a Rotating Brush to be Able to Produce a Foam that Has Well-Defined Properties and that Can Be Reproduced."; and translation into English. |
K27-Pr. Dr. R. Höhler; "Comparison Between Three-Dimensional Foams and Two-Dimensional Foams Which Are Produced by Squashing a Three-Dimensional Foam between a Two-Dimensional Foam."; Laboratoire de Physique de Milleux Divisés et Interfaces Université de Marne-la-Vallée and translation into English. |
K2-H. Mayer et al., "On the aetiology and treatment of varices of the lower extremities", Angiology, Chirurgische Praxis, pp. 521-528, (1957) with English translation. |
K3-Meyers'Encyclopedia, 5<SUP>th </SUP>Edition, vol. 15, pp. 386 (1985) with English translation. |
K4-Von P. Flückiger et al., "Beitrag sur Technik der ambulanten Varizenbehandlung", No. 12, pp. 617-621, Mar. 23, 1963. |
K5-Dr. Med. Jo{hacek over (ze Baridevic; "Varicosclerozation in Phlebological Practice"; The Journal for Doctors, in Clinical and Practice; XXI vol. No. 3, pp. 126-136; Jan. 11, 1989, and translation into English. |
K6-W. Gillesberger; "The Equipment of the Dermatologist Working in the Field of Phlebology", the Journal for Skin Diseases; vol. 44 (18), pp. 669-674; 1969 and translation into English. |
K7-Dr. E. Lunkenheimer; Letter to Chem. Fabrik Kreussler & Co.; Mar. 20, 1967 and translation into English. |
K8-Gianni Belcaro; "Micro-sclerotherapy"; Sclerotherapy in Venous Disease; pp. 89-95; 2002. |
K9-M. Schadeck; "Ultrasound-controlled Sclerotherapy of the Great Saphenous Veins"; Phlébologie; vol. 46, No. 4, pp. 673-682, 1993 and tranlsation into English. |
L. Ferguson, "Ligation of Varicose Veins, Ambulatory Treatment Preliminary to Sclerosing Injections", Annals of Surgery, vol. CII, pp. 304-314, 1935. |
L. Karmazsin et al., "Experimental Study of Lipid Peroxidation Following Intravenous Oxygen", Kiserletes Orvostudomany, vol. 39, pp. 342-348, 1987, with Abstract in English. |
L. Moszkowiez, "Treatment of Varicose Veins with Sugar Injections, combined with vein ligation", Zentralblatt fur Chirurgie, No. 28, pp. 1731-1736, 1927 and translation into English. |
L. Reiner, "The Activity of Anionic Surface Active Compounds in Producing Vascular Obliteration", Surface Active Sclerosing Agents, Proceedings of the Society for Experimental Biology and Medicine, vol. 62, pp. 49-54, May-Jun. 1946. |
M. Battezzati et al., "Treatment of Lower Limb Varices with Multiple Endermic Ligations and Sclerosant Injections Combined or not with Stripping of the Long Saphenous Vein's higher region", Minerva Chirurgica, pp. 936-939, 1952 and translation into English. |
M. Mairano, "Metodo combinato chirurgico-sclerosante o metodo sclerosante semplice nel trattamento delle varici essenziali?" Minerva Chirugica, vol. VI, No. 16, pp. 244-247, May 1951. |
M. Schadeck et al., "Echotomographie de la Sclerose", Phlebologie, vol. 44, No. 1, pp. 111-130, 1991. |
Meyers's Encyclopedia 5<SUP>th </SUP>Edition, 1895, vol. 15, pp. 386. |
P. Jaeger, "The Current Treatment Standard for Crural Ulcer and Varices", Deutsche Medizinische Wochenschrift, vol. 77, No. 14, pp. 421-425, Apr. 4, 1952 and translation into English. |
P. Piulaches et al., "Pathogenic Considerations on Varicose Veins Developed in Pregnancy", Lyon Chirurigical, Bulletin official de la Socirte de Chriurgie de Lyon, vol. 47, No. 3, pp. 263-278, Apr. 1952 and translation into English. |
P. Thibault et al., "Recurrent Varicose Veins", Phlebology, vol. 18, pp. 895-900, 1992. |
R. Bayeux, "Comparative Resistance of Dog and Rabbit to Intravenous Injection of Oxygen", Compt. Rend. vol. 156, pp. 1329-1331, 1913, with Abstract in English. |
R. de Somer-Leroy et al., "Echographie du Creux-Poplite Recherche D'Une Arteriole Petite Saphene Avant Sclerotherapie", Phlebologie, vol. 44, No. 1, pp. 69-78, 1991. |
R. E. Weston et al., "The Influence of Denitrogenation on the Response of Anesthetized Dogs to Intravenously Injected Oxygen", vol. 26, pp. 837-848, 1946. |
R. Foote, "Treatment", Varicose Veins, Chapter 5, p. 65 and 86, 1949. |
R. Jung, "Injection Treatment of Varicose Veins", Praxis, 195-198, 1950 and translation into English. |
R. M. Knight et al., "Ultrasonic Guidance of Injections into the Superficial Venous System", Phlebology, pp. 339-341, 1989. |
R. Rowden-Foote; "Varicose Veins Hermorrhoids and Other Conditions-Their Treatment by Injection"; London, H.K. Lewis & Co. Ltd.; pp. 13-45, 106-119; 1944. |
R. Zingg, "Experimental tests with the new sclerosing agent "Geigy"", pp. 1-9, 1948. |
R.M. Moore et al., "Injections of Air and Carbon Dioxide into a Pulmonary Vein", Annals of Surgery, vol. 112, pp. 212-218, 1940. |
R.S. Handley, "The Treatment of Varicose Veins", The Practitioner-Diseases of the Veins, No. 993, vol. 166, pp. 228-235, Mar. 1951. |
S. Efuin et al., "Oxygen Parameters of Blood and Tissues during Intravascular Oxygenation of the Organism", Eksperimental'naya Khirurgiya I Anesteziologiya, vol. 5, pp. 183-186, 1974, with Abstract in English. |
S. Efuin et al., Oxygen Parameters of Blood and Tissues during Intravascular Oxygenation of the Organism, Eksperimental'naya Khirurgiya I Anesteziologiya, vol. 5, pp. 71-74, 1974, with Abstract in English. |
Sigg, "Regarding treatment of varicose veins and their complications", Dermatologica, vol. 100, p. 317, 1950 and translation into English. |
V. Gorisch et al., "Appearance of intravenously given radioactive oxygen in expired air", Naunyn-Schmiedebergs Archiv fuer Experimentelle Pathologie und Pharmakologie, vol. 238, pp. 106-107, 1960, with Abstract in English. |
V. Gorisch et al., "Expiration of labeled oxygen after intravenous insufflation", Medicina Experimentalis, vol. 1, pp. 333-338, 1959, Abstract in English. |
Vin, "Echo-Sclerotherapy of the Small Saphenous Vein", Phlebologie, vol. 44, No. 1, pp. 79-84, 1991 with Abstract in English. |
W. Heyerdale et al., "Management of Varicose Veins of the Lower Extremities", Annals of Surgery, vol. 114, pp. 1042-1049, 1941. |
Written commentary tracking the DVDs submitted herein. |
Z.B. Shafi et al., "Factors Affecting High Shear Preparation of Albumin Microspheres", Pharmaceutical Sciences Research GRoup, p. 144P, 1990. |
Cited By (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080145401A1 (en) * | 1999-05-26 | 2008-06-19 | Tariq Osman | Generation of Therapeutic Microfoam |
US20060049269A1 (en) * | 1999-05-26 | 2006-03-09 | Tariq Osman | Generation of therapeutic microfoam |
US8091801B2 (en) | 1999-05-26 | 2012-01-10 | Btg International Limited | Generation of therapeutic microfoam |
US7604185B2 (en) | 1999-05-26 | 2009-10-20 | Btg International Ltd. | Generation of therapeutic microfoam |
US20090256006A1 (en) * | 1999-05-26 | 2009-10-15 | Tariq Osman | Generation of therapeutic microfoam |
US20090041827A1 (en) * | 1999-05-26 | 2009-02-12 | Btg International Ltd. | Therapeutic Microfoam |
US20070031345A1 (en) * | 2000-11-24 | 2007-02-08 | Harman Anthony D | Generation of therapeutic microfoam |
US7842282B2 (en) | 2000-11-24 | 2010-11-30 | Btg International Limited | Generation of therapeutic microfoam |
US20040156915A1 (en) * | 2000-11-24 | 2004-08-12 | Harman Anthony David | Generation of therapeutic microfoam |
US7842283B2 (en) | 2000-11-24 | 2010-11-30 | Btg International Limited | Generation of therapeutic microfoam |
US20070031346A1 (en) * | 2000-11-24 | 2007-02-08 | Harman Anthony D | Generation of therapeutic microfoam |
US8512680B2 (en) | 2001-08-08 | 2013-08-20 | Btg International Ltd. | Injectables in foam, new pharmaceutical applications |
US20080031827A1 (en) * | 2001-08-08 | 2008-02-07 | Maria Garcia-Olmedo Dominguez | Injectables in foam. New Pharmaceutical applications |
US20060062736A1 (en) * | 2003-11-17 | 2006-03-23 | Wright David D I | Therapeutic foam |
US8048439B2 (en) | 2003-11-17 | 2011-11-01 | Btg International Ltd. | Therapeutic foam |
US7731986B2 (en) | 2003-11-17 | 2010-06-08 | Btg International Ltd. | Therapeutic foam |
US7763269B2 (en) | 2003-11-17 | 2010-07-27 | Btg International Ltd. | Therapeutic foam |
US8323677B2 (en) | 2003-11-17 | 2012-12-04 | Btg International Ltd. | Therapeutic foam |
US20070003488A1 (en) * | 2003-11-17 | 2007-01-04 | Wright David D I | Methods of preparing a foam comprising a sclerosing agent |
US20060280690A1 (en) * | 2003-11-17 | 2006-12-14 | Wright David D I | Methods of preparing a foam comprising a sclerosing agent |
US20070104651A1 (en) * | 2003-11-17 | 2007-05-10 | Wright David D I | Therapeutic foam |
US20070003489A1 (en) * | 2003-11-17 | 2007-01-04 | Wright David D I | Therapeutic foam |
US20090124704A1 (en) * | 2005-05-13 | 2009-05-14 | William John Jenkins | Therapeutic foam |
US8703827B2 (en) | 2005-05-13 | 2014-04-22 | Btg International Ltd. | Therapeutic foam |
US9687455B2 (en) | 2014-08-14 | 2017-06-27 | John Daniel Dobak | Sodium tetradecyl sulfate formulations for treatment of adipose tissue |
US9351945B1 (en) | 2015-02-27 | 2016-05-31 | John Daniel Dobak, III | Reduction of adipose tissue |
US9844520B2 (en) | 2015-02-27 | 2017-12-19 | John Daniel Dobak, III | Reduction of adipose tissue |
US10485767B2 (en) | 2015-02-27 | 2019-11-26 | John Daniel Dobak, III | Reduction of adipose tissue |
US11065210B2 (en) | 2015-02-27 | 2021-07-20 | 10Xbio, Llc | Reduction of adipose tissue |
Also Published As
Publication number | Publication date |
---|---|
US5676962A (en) | 1997-10-14 |
ES2068151A1 (en) | 1995-04-01 |
DK0656203T3 (en) | 1999-11-01 |
USRE40640E1 (en) | 2009-02-17 |
DE69418286T2 (en) | 1999-10-14 |
ES2131689T3 (en) | 1999-08-01 |
AU7001294A (en) | 1995-01-17 |
WO1995000120A1 (en) | 1995-01-05 |
GR3030248T3 (en) | 1999-08-31 |
EP0656203B3 (en) | 2011-01-26 |
ATE179598T1 (en) | 1999-05-15 |
ES2131689T7 (en) | 2012-03-16 |
EP0656203B1 (en) | 1999-05-06 |
DE69418286D1 (en) | 1999-06-10 |
EP0656203A1 (en) | 1995-06-07 |
ES2068151B1 (en) | 1995-11-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
USRE38919E1 (en) | Injectable microfoam containing a sclerosing agent | |
EP1701701B1 (en) | Methods of preparing a foam comprising a sclerosing agent | |
Cabrera et al. | Treatment of varicose long saphenous veins with sclerosant in microfoam form: long-term outcomes | |
Bookstein et al. | Pulsed-spray pharmacomechanical thrombolysis: preliminary clinical results | |
AU2013353931B2 (en) | Hemostatic foam | |
Johns et al. | Prevention of coronary artery reocclusion and reduction in late coronary artery stenosis after thrombolytic therapy in patients with acute myocardial infarction. A randomized study of maintenance infusion of recombinant human tissue-type plasminogen activator. | |
Eckmann et al. | Microvascular embolization following polidocanol microfoam sclerosant administration | |
WO2015185554A2 (en) | Methods, devices, systems and kits for preparing compositions for care and repair of varicose veins | |
US7314466B2 (en) | Minimally invasive vascular surgery | |
JP2720101B2 (en) | W / O / W composite emulsion for injection and method for producing the same | |
Do et al. | Catheter thrombolysis with streptokinase, urokinase, and recombinant tissue plasminogen activator for peripheral arterial occlusion | |
Goto et al. | Effect of high-dose of methylprednisolone on tourniquet ischaemia | |
Stoughton et al. | Treatment of chronic venous insufficiency with foam sclerotherapy | |
Serkan et al. | Low temperature offers better foam stability | |
Montalescot | Defining standards of care for facilitated and direct percutaneous coronary intervention | |
Farret et al. | Preparation, characterization and in vitro thrombolytic activity of a novel streptokinase foam | |
JPS62155222A (en) | Antithrombotic composition | |
US8512680B2 (en) | Injectables in foam, new pharmaceutical applications | |
Cabrera et al. | Sclerotherapy in vascular malformations | |
Angelov et al. | History of foam sclerotherapy—a review | |
Savitha et al. | Foam Sclerotherapy | |
Cabrera | Dr J. Cabrera is the creator of the patented polidocanol microfoam | |
Eglin et al. | The Action of Calciparine in the Prevention of Premature Delivery | |
Verhaeghe | Regional thrombolysis in lower limb ischemia: new pharmacological and nonpharmacological aspects | |
Cabrera et al. | Sclerotherapy 22 Malformations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FEPP | Fee payment procedure |
Free format text: PAYER NUMBER DE-ASSIGNED (ORIGINAL EVENT CODE: RMPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |